S&P 500 Financials Sector SEC Filings — March 19, 2026

19-03-2026

FreightCar America, Inc. (RAIL) filed a DEF 14A proxy statement for its virtual Annual Meeting of Stockholders on April 10, 2026, at 10:00 a.m. Central Time, to elect three Class III directors for three-year terms, approve on an advisory basis the compensation of Named Executive Officers, and ratify Grant Thornton LLP as independent registered public accounting firm for fiscal year 2026. The record date is February 10, 2026, with 19,062,155 shares of common stock outstanding entitled to vote. Proxy materials are being mailed on or about March 19, 2026.

• ·Meeting held virtually only via live webcast at www.meetnow.global/MFVJ6LW
• ·Voting requires 15-digit control number for proxy submission via internet, phone, or mail
• ·Quorum requires majority of shares outstanding on record date present virtually or by proxy

19-03-2026

DarioHealth Corp. reported total revenues of $22.4M for FY 2025, down 17% YoY from $27.0M, driven by a 26% decline in services to $14.9M despite an 8.5% increase in consumer hardware to $7.4M. Operating expenses fell 31% to $49.3M, resulting in a smaller operating loss of $36.7M versus $57.7M prior year, and net loss improved slightly to $41.7M from $42.7M; however, cash and equivalents dropped to $21.8M from $27.8M, total assets declined to $110.1M from $118.9M, and stockholders' equity decreased to $67.9M from $72.0M amid significant share dilution to 6.9M shares outstanding.

• ·Cash used in operating activities improved to $(25.9M) from $(38.6M) YoY.
• ·Non-GAAP adjusted loss improved to $(24.2M) from $(33.8M), a $9.6M betterment.
• ·Accumulated deficit worsened to $(452.1M) from $(390.3M).
• ·Basic and diluted loss per share improved to $10.12 from $12.27.
• ·Weighted average shares increased to 3,983K from 2,452K.

19-03-2026

RYVYL Inc. adjourned its Special Meeting of Shareholders on March 18, 2026, to vote on the planned merger with RTB Digital, Inc. (Roundtable), reconvening virtually on March 25, 2026, at 4pm EST. Approximately 99% of votes cast supported the merger, with 43% of entitled shares voted, requiring only an additional 7% in favor to approve; however, the adjournment highlights that quorum or majority threshold has not yet been met. The company urges unvoted shareholders to participate promptly via Kingsdale Advisors.

• ·Record date for Special Meeting: February 6, 2026 (unchanged)
• ·Virtual meeting link: http://www.virtualshareholdermeeting.com/RVYL2026SM
• ·Voting assistance contact: Kingsdale Advisors at 888-518-6812 or contactus@kingsdaleadvisors.com

19-03-2026

Brunswick Corporation filed a DEFA14A additional proxy statement for its annual shareholder meeting on May 6, 2026, seeking votes on the election of ten director nominees, an advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026. The board recommends voting 'For' all proposals. No financial performance metrics or period-over-period comparisons are provided in this filing.

• ·Vote deadline: 11:59 PM ET on May 5, 2026 (May 1, 2026 for employee plan shares)
• ·Material request deadline: April 22, 2026
• ·Proxy voting options: www.ProxyVote.com, 1-800-579-1639, sendmaterial@proxyvote.com
• ·Company address: 26125 N. Riverwoods Blvd., Suite 500, Mettawa, IL 60045-3420

19-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 19, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'AITX's RAD Books Hundreds of SARA Licenses as Customers Expand After Initial Deployment.' The press release is furnished as Exhibit 99.1 and is not deemed filed or material.

• ·Filed by newsfilecorp.com
• ·Registrant details: Nevada incorporation, Commission File Number 000-55079, IRS Employer Identification No. 27-2343603, principal offices at 10800 Galaxie Avenue, Ferndale, Michigan 48220

19-03-2026

AMERICAN VANGUARD CORPORATION (as Holdings) and AMVAC CHEMICAL CORPORATION (as Borrower) entered into a Credit and Guaranty Agreement dated March 13, 2026, with Wilmington Trust, National Association as Administrative Agent and certain lenders, establishing a senior secured term loan facility with an aggregate principal amount of $225 million. The facility provides financing subject to covenants, representations, and events of default, with interest rates starting at Term SOFR plus 8.25% or Base Rate plus 7.25%, eligible to step down based on improvements in the Consolidated Total Leverage Ratio below thresholds like 4.00:1.00. No prior period financial performance data or comparisons are disclosed in the filing.

• ·Compliance Certificate due two business days after quarterly financials for fiscal quarter ending June 30, 2026, to potentially adjust Applicable Margin.
• ·ABL Facility permitted if approved by Required Lenders, secured junior to term loan on non-ABL Priority Collateral.

19-03-2026

Legence Corp. filed Amendment No. 1 to its January 2, 2026 Form 8-K to include the required audited consolidated financial statements of acquired business The Bowers Group, Inc. (Bowers) for the year ended September 30, 2025 (Exhibit 99.1), and unaudited pro forma condensed combined financial information for Legence and subsidiaries as of September 30, 2025, for the nine months ended September 30, 2025, and the year ended December 31, 2024 (Exhibit 99.2). The acquisition of 100% of Bowers' equity interests was consummated on January 2, 2026, via Legence Corp. and its subsidiary Legence Subsidiary Holdings, LLC. No specific financial metrics or performance changes are disclosed in the filing text.

• ·Auditor consent for Bowers financials provided by Lanigan Ryan, P.C. (Exhibit 23.1)
• ·Securities: Class A common stock (LGN) on Nasdaq Stock Market LLC
• ·Company headquarters: 1601 Las Plumas Avenue, San Jose, CA 95133

19-03-2026

SUNation Energy reported robust Q4 and FY 2025 financial results, with Q4 revenue surging 77% YoY to $27.2M, gross margin expanding to 40.7%, and Adjusted EBITDA reaching $4.1M versus a prior-year loss; FY revenue grew 26% YoY to $71.9M, beating the $65-70M guidance, with gross profit up 35% to $27.5M and Adjusted EBITDA at $2.5M. The company strengthened its balance sheet, ending with $7.2M liquidity, positive $1.1M working capital, and total debt reduced 57% to $8.1M from $19.1M. However, FY operating loss was still $1.7M (improved from $12.3M) and net loss $10.9M (from $15.8M), with management noting significant 2026 challenges from the Section 25D tax credit expiration.

• ·SUNation NY remained the leading solar contractor in its region with Long Island aggregate installed capacity up 29% YoY.
• ·Operating expenses declined 10.8% YoY to $29.2M in FY 2025.
• ·Cash flow from financing activities was $5.1M, used to pay down $12.6M of debt and obligations.

19-03-2026

Catalyst Pharmaceuticals, Inc. (CPRX) filed an 8-K/A on March 19, 2026, to correct a scrivener’s error in the signature date of its prior 8-K filed on March 18, 2026. The underlying event discloses a District Court for the District of New Jersey order delaying the bench trial against Hetero USA, Inc. from March 23, 2026, to May 18, 2026, concerning the validity of the company's Orange Book-listed patents for FIRDAPSE® that expire in 2032, 2034, and 2037. No other changes were made to the original filing.

• ·District Court for the District of New Jersey issued the trial delay order.
• ·Patents are Orange Book-listed.

19-03-2026

SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced on March 17, 2026, a proposed underwritten public offering of common stock and pre-funded warrants, with underwriters granted a 30-day option to purchase up to an additional 15% of the securities. Net proceeds, along with existing cash, will primarily fund the development of clinical-stage candidate SAB-142 through ongoing and planned trials, manufacturing, regulatory activities, and general corporate purposes. The offering is subject to market conditions with no assurance of completion or final terms.

• ·Shelf registration statement on Form S-3 (No. 333-292482) filed December 29, 2025, declared effective January 7, 2026.
• ·Joint book-running managers: Jefferies, UBS Investment Bank, Citigroup, Barclays; lead manager: Chardan.

19-03-2026

Modiv Industrial, Inc. announced it will report financial results for the quarter and full year ended December 31, 2025, after market close on March 25, 2026. The company declared a quarterly dividend of $0.4609375 per share on its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, payable April 15, 2026, and monthly distributions of $0.10 per share on Class C Common Stock for April, May, and June 2026, equivalent to an annualized $1.20 per share. No comparative financial metrics were provided in the filing.

• ·Board authorized dividends and distributions on March 17, 2026.
• ·Series A Preferred record date: March 31, 2026.
• ·Common Stock record dates: April 30, May 29, June 30, 2026.
• ·Common Stock payment dates: May 15, June 15, July 15, 2026.

19-03-2026

Selectis Health, Inc. appointed Richard Huebner, age 68, as a new member of its Board of Directors effective March 12, 2026. Mr. Huebner, senior managing partner at GVC Capital LLC since 2001, has extensive experience in investment banking, compliance, and legal roles at firms including Fiserv Correspondent Services and Hanifen Imhoff Inc. He will receive an annual stipend of $30,000 under the company's Outside Directors Compensation Plan.

• ·Richard Huebner served as registered investment advisor (2000-2001), Executive Vice President at Fiserv Correspondent Services (1984-2000), and various roles at Hanifen Imhoff entities (1979-1997) and First Mid America, Inc. (1980-1983).
• ·Education: Bachelor’s degree from Hastings College (1979); Juris Doctorate from University of Nebraska (1982).

19-03-2026

News Corporation filed an 8-K on March 19, 2026, disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program for Class A (NWSA) and Class B (NWS) common stock. The program authorizes repurchases up to $1B in aggregate, with daily ASX disclosures required for any transactions; Exhibits 99.1 and 99.2 contain the specific details. No actual repurchase volumes or impacts were detailed in the filing.

• ·Securities traded on The Nasdaq Global Select Market.
• ·Event date: March 18, 2026; Filing date: March 19, 2026.

19-03-2026

Gold Resource Corporation reported 2025 full-year production of 23,125 gold equivalent ounces (4,944 gold oz and 1,461,898 silver oz) from Don David Gold Mine, reflecting a YoY increase in AuEq output driven by strong Q4 performance (10,413 AuEq oz) and higher silver volumes, with realized prices of $3,657/oz gold and $45.48/oz silver, cash costs of $2,205/AuEq oz, and AISC of $2,807/AuEq oz. The company ended with $25M cash (up $23.4M YoY) and $32M working capital (up 1,424% from $2.1M), bolstered by $22.5M+ in financings including offerings and a $4M tax refund. However, gold production declined YoY, early 2025 quarters showed lower tonnes milled and AuEq output versus 2024, and total capital/exploration spend rose to $24M.

• ·DDGM received Mexican ESR award for 11th consecutive year.
• ·Sustaining investments $12.4M (up from $8.6M YoY); growth investments $11.6M (up from $2.3M YoY).
• ·January 2025 registered direct offering $2.5M; February 2025 sale of Green Light Metals interest $0.9M.
• ·September 2025 offering included 14.2M shares ($6.4M fair value) for non-cash term loan payoff.
• ·Exploration focused on grade-control drilling at Three Sisters and Arista; surface drilling started at Alta Gracia Q4 2025.

19-03-2026

On March 17, 2026, The Cannabist Company Holdings Inc. secured a further extension of a forbearance agreement from an ad hoc group of noteholders for its 9.25% Senior Secured Notes due December 31, 2028, and 9.00% Senior Secured Convertible Notes due December 31, 2028, postponing any exercise of remedies until March 25, 2026. This development signals ongoing financial stress and potential covenant issues under the amended indenture. No financial metrics or performance data were disclosed.

• ·Registrant is an emerging growth company.
• ·Principal executive offices: 321 Billerica Road, Chelmsford, Massachusetts 01824.
• ·Telephone: (978) 910-1486.
• ·No securities registered pursuant to Section 12(b) of the Act.

19-03-2026

Marker Therapeutics reported strong Phase 1 APOLLO clinical data for MT-601 with a 66% objective response rate (50% complete responses) in relapsed non-Hodgkin lymphoma and 78% in Hodgkin lymphoma, plus promising pancreatic cancer results (up to 84.6% disease control rate) published in Nature Medicine. Financially, cash stood at $17M at year-end 2025, funding operations through Q4 2026, but revenues fell 46% YoY to $3.5M, net loss widened 14% to $12.2M from $10.7M, despite R&D expenses declining 12% to $11.8M and flat G&A at $4.2M. Upcoming catalysts include APOLLO data updates and pancreatic program start in Q2 2026.

• ·Dose expansion in APOLLO enrolling relapsed DLBCL patients at 400×10⁶ cells; no DLTs or ICANS reported.
• ·Manufacturing technical transfer with Cellipont Bioservices expected Q2 2026.
• ·Supported by non-dilutive grants from NIH (R44CA291521, R44CA295168, 1R44CA285177), FDA (R01FD007272), CPRIT (DP250150, DP210042).

19-03-2026

Innventure, Inc. filed a Form S-3 registration statement on March 18, 2026, to register the resale of common stock by certain selling stockholders, consolidating three prior Form S-1 registrations (File Nos. 333-282971, 333-286558, and 333-291034). The filing covers already issued outstanding shares or those issuable upon conversion or exercise of previously disclosed securities, with no new equity issuances or stockholder dilution. The company will not receive proceeds from these resales, except potentially from its Standby Equity Purchase Agreement with YA II PN, Ltd., dated October 24, 2023, or cash exercises of certain warrants.

• ·Commission File Number: 001-42303
• ·I.R.S. Employer Identification Number: 93-4440048
• ·Prior Form S-1 File Nos.: 333-282971, 333-286558, 333-291034

19-03-2026

Global Net Lease, Inc. announced the declaration of quarterly dividends on its preferred stocks on March 19, 2026: $0.453125 per share for 7.25% Series A, $0.4296875 per share for 6.875% Series B, $0.46875 per share for 7.50% Series D, and $0.4609375 per share for 7.375% Series E, all payable on April 15, 2026 to holders of record on April 3, 2026. These dividends align with the stated coupon rates, providing expected returns to preferred shareholders.

• ·All preferred stocks listed on New York Stock Exchange
• ·Company address: 650 Fifth Avenue, 30th Floor, New York, New York 10019
• ·Telephone: (332) 265-2020

19-03-2026

Republic Airways Holdings Inc. reported FY2025 revenues of $1,676.5M, up 13.7% YoY from $1,474.0M, with operating income rising 22.8% to $168.3M and Adjusted EBITDA surging 32.9% to $341.7M, driving net income to $76.2M (+18.0%). However, executive separation and merger-related costs jumped to $47.1M from $3.2M, total liquidity declined 1.1% to $319.9M, and net cash used in investing activities ballooned to $350.9M. In FY2024 vs FY2023, revenues grew modestly 3.1% but Adjusted EBITDA fell 12.8% to $257.2M.

• ·Net cash provided by operating activities increased 42.4% to $322.0M in FY2025 from $226.1M.
• ·Net cash used in investing activities worsened to $350.9M in FY2025 from $105.5M.
• ·Income tax expense rose 66.8% to $37.2M in FY2025.
• ·Depreciation and amortization increased 7.9% to $126.3M in FY2025.
• ·Marketable securities declined 15.3% to $162.2M in FY2025.

19-03-2026

Artius II Acquisition Inc., a SPAC, reported net income of $136k for the year ended December 31, 2025, compared to a $85k net loss for the period from inception (July 25, 2024) through December 31, 2024, driven by $8.1M interest income from the Trust Account offsetting a $7.9M operating loss that included a $6M advisory fee. Total assets grew to $228.3M primarily from $228.1M in the Trust Account following the IPO of 22M Class A shares, but shareholders' deficit widened significantly to $13.8M due to accretion of $18.8M. Cash position was minimal at $32k.

• ·IPO involved sale of public units generating $219.75M net proceeds.
• ·Founder shares: 250,000 Class B shares forfeited by Sponsor.
• ·Promissory note to related party repaid $135k in 2025.
• ·Basic and diluted EPS of $0.01 for redeemable and non-redeemable Class A shares in 2025.
• ·Class B shares EPS not applicable in 2025; prior period loss per share ($0.02).

19-03-2026

Rice Acquisition Corp 3, a SPAC, reported net income of $2.85M for the period from inception (June 6, 2025) to December 31, 2025, driven by $3.4M interest income from the Trust Account offsetting a $548K operating loss from formation and administrative costs. Total assets stood at $351.3M, primarily $348.4M cash in the Trust Account from IPO proceeds (34.5M Class A shares at $10.10 redemption value), while shareholders' deficit was $13.2M due to accretion and transaction costs. No business combination has occurred, with cash outside trust at $2.6M and ongoing liabilities including $13.4M deferred underwriting fees.

• ·IPO-related financing: $338.1M proceeds from Units net of underwriting discounts; $10.65M from Private Placement Warrants
• ·Cash flows: Net used in operations $(467.5K); investing $(345M) into Trust; financing $348.1M
• ·Non-cash: Accretion of Class A shares to redemption $28.9M; transaction costs allocated $257K

19-03-2026

United Bancorp, Inc. filed an amended Form 10-K/A for the fiscal year ended December 31, 2025, on March 19, 2026, primarily incorporating exhibits by reference including governance documents, executive change-in-control agreements, supplemental life insurance and deferred compensation plans, stock incentive plans, subordinated debt agreements, the 2025 Annual Report, insider trading policies, subsidiaries list, audit consents, and Sarbanes-Oxley certifications. Signatures were provided by CEO Scott A. Everson, CFO Randall M. Greenwood, and directors on March 18, 2026. No financial performance metrics, period-over-period comparisons, or material updates to results are detailed in the filing content.

• ·Filing covers FY 2025 (January 1, 2025 to December 31, 2025).
• ·Key exhibits include Clawback Policy (Exhibit 97) and Insider Trading Policies and Procedures (Exhibit 19).

19-03-2026

Micron Technology reported exceptional Q2 FY2026 results with revenue surging 196% YoY to $23.9B from $8.1B, gross margin expanding dramatically to $17.8B (499% YoY increase), and net income skyrocketing 771% YoY to $13.8B. For the six months ended February 26, 2026, revenue more than doubled 124% YoY to $37.5B with net income up 451% to $19.0B. The balance sheet strengthened significantly, with cash and equivalents rising 44% to $13.9B, total assets up 23% to $101.5B, and long-term debt reduced 32% to $9.6B, though inventories dipped slightly 1% QoQ.

• ·EPS diluted Q2 FY2026: $12.07 (vs $1.41 YoY, +756%)
• ·R&D expense Q2: $1.25B (up 39% YoY)
• ·Stock-based compensation expense six months: $599M
• ·Dividends declared Q2: $0.115 per share ($132M total); six months $0.23 per share ($264M total)
• ·Several senior notes repaid in period including 2028 Notes, 2029 A/B Notes, 2029 Term Loan A, 2030 Notes (October 2025/February 2026)

19-03-2026

Inception Growth Acquisition Ltd, a blank check company, withdrew $5,269.61 of interest earned from its trust account on March 16, 2026, to pay taxes, leaving approximately $2.13M remaining in the trust. This routine disclosure under Item 8.01 provides transparency on trust account activity amid ongoing operations as an emerging growth company listed on OTC Markets.

• ·Securities traded on OTC Markets Group, Inc.: IGTAU (Units), IGTA (Common Stock, $0.0001 par), IGTAW (Warrants exercisable at $11.50), IGTAR (Rights for 1/10th share)
• ·Company is an emerging growth company under Rule 405/12b-2
• ·Filing date: March 19, 2026; Event date: March 16, 2026

19-03-2026

Pelthos Therapeutics reported Q4 2025 ZELSUVMI net product revenue of $9.1M, up 28% QoQ from $7.1M in Q3, with total 2025 net product revenue reaching $16.2M since July launch and 129% QoQ unit growth to 6,232 units. However, Q4 operating loss improved to $12.0M from $15.4M in Q3, but net loss widened to $21.7M due to a $15.0M change in fair value of convertible debt, amid high SG&A of $18.5M and full-year net loss of $43.3M. The company completed acquisitions of XEPI in Nov 2025 and XEGLYZE in Jan 2026, raised $18M in convertible notes and $30M from a $50M term loan, bolstering cash to $18M as of Dec 31, 2025.

• ·Cash grew to $18.0M as of Dec 31, 2025 from $0.5M in 2024; total assets $130.4M vs $1.4M.
• ·Q4 COGS $1.7M vs $2.3M Q3; adjusted COGS $0.1M Q4 vs $0.4M Q3.
• ·Impetigo affects ~3M people/year in U.S.; head lice ~6-12M infestations/year.

19-03-2026

Titan Mining Corp reported FY2025 revenue of $74.2M, up 15% YoY from $64.3M, with income from mine operations rising 38% to $17.7M driven by higher production and sales. However, the company swung to a net loss before tax of $28k from a $6.7M profit in 2024, due to increased G&A expenses (up 31%), new $2.0M graphite project costs, and a $5.7M loss on derivative financial instruments related to special warrants. Total assets grew 36% to $75.0M, supported by 72% higher cash at $17.5M, though operating cash flow declined 12% to $12.6M.

• ·1.5:1 share consolidation on November 3, 2025, with EPS adjusted accordingly.
• ·Weighted average sale prices: STD Purity Flake $1,575/Mt; High Purity Micronized Flake $5,185/Mt; CSPG Anode $11,193/Mt.
• ·Related party loans decreased to $17.1M from $22.0M; debt reduced to $9.1M total from $10.1M current.
• ·Investing cash outflow $12.7M mainly for mineral properties additions vs $1.8M prior year.

19-03-2026

Lithium Americas Corp. (LAC) reported a widened net loss of $86.3M for the year ended December 31, 2025, compared to $42.6M in 2024, with net loss attributable to stockholders rising to $122.1M from $42.5M, driven by higher G&A expenses ($52.8M vs. $28.1M, +88%) and transaction costs ($32.3M vs. $22.2M, +45%), despite a $160M gain on warrant obligations offset by a $171M loss on convertible debt. Balance sheet growth was robust with cash and restricted cash up 52% to $905.6M, total assets more than doubling to $2.58B from $1.04B, and mineral properties, plant & equipment surging to $1.34B from $399M amid $765M investing outflows. However, total liabilities ballooned nearly 10-fold to $992.4M from $99.6M due to new DOE loan ($351M), convertible debt ($160M), and warrant obligations.

• ·Net cash provided by financing activities: $1,137.6M in 2025 vs. $589.1M in 2024 (+93%).
• ·Proceeds from public offerings: $401.2M in 2025.
• ·Proceeds from non-controlling interest: $100M in 2025 (Lithium Nevada Ventures LLC).
• ·Non-controlling interest increased to $527.9M from $310.3M.
• ·Weighted average shares outstanding: 243,658 (2025) vs. 200,817 (2024).

19-03-2026

Kolibri Global Energy Inc. (KGEI), a foreign private issuer and emerging growth company, filed its Form 40-F Annual Report for the fiscal year ended December 31, 2025, incorporating by reference its Annual Information Form (AIF), Management’s Discussion and Analysis (MD&A), and audited consolidated financial statements for 2025 and 2024 prepared under IFRS. The company reported 35,471,833 common shares outstanding as of December 31, 2025, with shares listed on Nasdaq Capital Market (KGEI) and Toronto Stock Exchange. Management certified effective disclosure controls and internal controls over financial reporting, with no material changes or errors noted.

• ·Audit committee financial expert: Doug Urch (independent).
• ·Principal executive offices: 925 Broadbeck Drive, Suite 220, Thousand Oaks, CA 91320.
• ·Shareholder special meeting on November 25, 2025, limited authorized common shares to 37,367,894 without approval.
• ·No off-balance sheet arrangements material to investors.
• ·No waivers to Code of Business Conduct and Ethics in 2025.

19-03-2026

Cardinal Infrastructure Group Inc. (CDNL) reported full year 2025 revenue of $456M, up 45% YoY (33% organic) from $315.2M in 2024, Adjusted EBITDA of $81.5M up 44% YoY, and backlog of $682M up 33% from $512M. However, net income grew only 10% to $31.1M, gross profit margin declined to 14.0% from 14.8%, EBITDA margin fell to 15.8% from 16.9%, reflecting higher acquisition, IPO, and capex expenses. The company affirmed 2026 guidance of $665-678M revenue and 20%+ Adjusted EBITDA margin, post-acquisition of A.L. Grading Contractors on Feb 18, 2026.

• ·Completed IPO in December 2025 raising $139.8M.
• ·Acquired A.L. Grading Contractors on February 18, 2026, first expansion into Georgia.
• ·2026 guidance: Revenue $665-678M; Adjusted EBITDA margin 20%+.
• ·Conference call on March 19, 2026 at 10:30 a.m. ET.

19-03-2026

Vine Hill Capital Investment Corp. announced via press release that the physical location for its Extraordinary General Meeting on March 27, 2026, at 10:00 a.m. ET—to approve the proposed business combination with CoinShares International Limited and Odysseus Holdings Limited—has changed to the offices of Paul Hastings LLP in Los Angeles, CA. The virtual meeting link remains unchanged at https://www.cstproxy.com/vinehillcapital/2026, with no alterations to the date, time, or agenda. This update is part of ongoing M&A communications ahead of the shareholder vote.

• ·Definitive proxy statement filed with SEC on March 16, 2026.
• ·Shareholder record date for voting: March 2, 2026.
• ·New physical venue: 515 South Flower Street, 25th Floor, Los Angeles, California 90071.
• ·Registrant is an emerging growth company.

19-03-2026

Accenture plc reported revenues of $18.0B for the three months ended February 28, 2026, up 8.3% YoY from $16.7B, and $36.8B for the six months ended February 28, 2026, up 7.1% YoY from $34.3B, with operating income rising 11.1% to $2.5B in Q2 and 3.3% to $5.4B for H1. However, net income attributable to Accenture plc increased only 2.1% to $1.8B in Q2 but declined 0.8% to $4.0B for H1 YoY, and cash and cash equivalents fell to $9.4B from $11.5B at August 31, 2025 amid heavy share repurchases and acquisitions. Diluted EPS rose modestly to $2.93 in Q2 (+3.9% YoY) and $6.47 for H1 (+0.8% YoY).

• ·Net cash provided by operating activities for six months: $5.48B, up from $3.88B YoY.
• ·Goodwill increased to $24.58B from $22.54B, reflecting acquisitions.
• ·Treasury shares at cost: ($11.0B) as of Feb 28, 2026, up from ($7.75B).
• ·Cash dividends per Class A share: $1.63 for three months, $3.26 for six months.

19-03-2026

Lands’ End reported fourth quarter FY25 net revenue growth of 4.7% to $462.4M with GMV up mid-single digits, driven by U.S. Digital (+5.3%), Outfitters (+9.6%), and Europe eCommerce (+9.3%), however Licensing and Retail declined 8.4% and gross margin contracted 30bps to 45.3%. Full year FY25 net revenue fell 2.0% to $1.34B amid declines in U.S. eCommerce (-1.5%), Europe eCommerce (-12.5%), and Licensing and Retail (-22.0%), but Adjusted EBITDA rose 10% to $102.3M, gross margin expanded 80bps to 48.7%, and Adjusted net income more than doubled to $26.8M. The company announced a transformative JV with WHP Global, contributing its IP for $300M cash (50% controlling stake) to fully repay $234M term loan debt, plus a $100M tender offer at $45/share.

• ·Q4 Adjusted EBITDA $47.4M vs $43.7M prior year.
• ·FY25 U.S. eCommerce net revenue $829.8M, down 1.5% YoY.
• ·FY25 Third Party net revenue up 9.2% to $91.2M.
• ·Net cash provided by operating activities $49.6M in FY25 vs $53.1M in FY24.
• ·WHP Global tender offer at $45.00 per share, potentially owning up to 7% of shares.
• ·JV closing expected by end of Q1 FY26.

19-03-2026

Darden Restaurants reported Q3 FY26 total sales up 5.9% YoY to $3.3B, driven by 4.2% blended same-restaurant sales growth, with LongHorn Steakhouse (+7.2%) and Other Business (+13.9%) leading, while Olive Garden (+3.2%) and Fine Dining (+2.1%) showed more modest gains; adjusted diluted EPS rose 5.4% to $2.95, though reported EPS declined to $2.68 from $2.74 amid closure costs and impairments. YTD segment profit for Fine Dining fell 3.1% to $174.1M despite overall YTD sales growth of 7.8% to $9.5B. The company repurchased $127M in stock, declared a $1.50 quarterly dividend, and updated FY26 outlook for ~9.5% sales growth and adjusted EPS of $10.57-$10.67.

• ·Q3 Olive Garden segment profit up 4.1% to $320M; LongHorn up 4.8% to $159M; Other Business up 3.1% to $108.8M.
• ·FY26 outlook includes ~2% sales growth from 53rd week and ~$0.25 EPS impact; effective tax rate ~12.5%; ~116.5M weighted average diluted shares.
• ·Quarterly dividend of $1.50 per share payable May 1, 2026 to shareholders of record April 10, 2026.
• ·Investor conference call held March 19, 2026 at 8:30am ET.

19-03-2026

Chicago Atlantic BDC, Inc. (LIEN) reported Q4 2025 total investment income of $14.2M (up 12.5% YoY) and net investment income of $8.3M ($0.36/share), with full-year NII of $33.1M ($1.45/share, up 250% YoY); NAV per share rose slightly to $13.30 (up 0.8% YoY and 0.2% QoQ). The portfolio stood at $333.3M across 39 companies with no non-accruals and a 15.8% weighted average yield, while funding $31.7M in Q4 and $93.9M subsequently; however, liquidity declined to $47.5M as of March 18, 2026 from $77.9M at year-end, and Q4 saw minor unrealized depreciation of $20.6k. The Board declared a steady $0.34/share dividend (sixth consecutive quarter), payable April 14, 2026.

• ·Principal amortization and repayments of $11.0M in Q4 2025.
• ·Subsequent to year-end: two positions paid off totaling $13.6M; $54.5M outstanding on senior credit facility as of March 18, 2026.
• ·Pipeline exceeding $732M as of Dec 31, 2025.

19-03-2026

Solo Brands reported fiscal Q4 2025 net sales of $94.0 million, down 34.5% YoY from $143.5 million, and full-year 2025 net sales of $316.6 million, down 30.4% YoY from $454.6 million, primarily due to sharp declines in Solo Stove (Q4 -38.3%, FY -43.8%). However, cost-saving actions drove Q4 Adjusted EBITDA to $9.6 million (10.2% margin, up from 4.4%), SG&A expenses down 38.8% to $50.1 million, and positive operating cash flow for the third straight quarter, while Chubbies full-year sales grew 9.1% with EBITDA margin expansion to 18.2%. Balance sheet showed cash up to $20.0 million and inventory down to $81.6 million, though net loss widened in Q4 to $83.2 million.

• ·Restructuring charges Q4 2025: $75.5M (up from $52.5M YoY); FY 2025: $93.5M (down from $136.1M).
• ·2025 Term Loan entered June 13, 2025: $240.0M principal; Revolving facility: $90.0M commitment ($54.9M availability as of Dec 31, 2025).
• ·Conference call: March 19, 2026 at 9:00 a.m. ET.

19-03-2026

DevvStream Corp. reduced outstanding debt by approximately $5.9 million net of a new $700,000 0% interest loan from Helena Partners, through Focus Impact Partners converting $5.5 million of 5.3% notes and fees into equity at a 12.9% premium, and prepaying $1.1 million to Helena from released $1.2 million collateral. These moves strengthen the balance sheet and signal partner confidence. However, forward-looking risks highlight potential insufficient liquidity from the new loan, Nasdaq delisting threats, and operational constraints from existing debt.

• ·FIP 5.3% convertible notes due November 2026
• ·Helena convertible note dated July 17, 2025
• ·Helena interest waiver through May 2026
• ·New Helena loan due March 2027
• ·Announcement date: March 13, 2026
• ·Filing date: March 19, 2026

19-03-2026

Larimar Therapeutics reported widening net losses for Q4 and full year 2025 of $62.5M ($0.73/share) and $165.7M ($2.27/share), respectively, compared to $28.8M and $80.6M in 2024, primarily due to increased R&D expenses from nomlabofusp manufacturing scale-up ($59.4M Q4, $154.2M FY vs $26.7M and $73.3M prior year). Positively, the company received FDA Breakthrough Therapy Designation for nomlabofusp in FA, confirmed alignment on BLA submission seeking accelerated approval in June 2026, and strengthened its balance sheet with $107.6M net proceeds from a February 2026 public offering, yielding pro forma cash of $244.5M and runway into Q2 2027.

• ·Plan to report topline open label study data in Q2 2026 to support BLA.
• ·Initiate screening in global Phase 3 study in Q2 2026, dosing first patient mid-2026.
• ·U.S. launch targeted for first-half 2027, if approved.
• ·Cash and cash equivalents $85.4M, short-term marketable securities $51.4M as of Dec 31, 2025 (down from prior year).

19-03-2026

GE HealthCare Technologies Inc. (GEHC) issued a DEFA14A proxy notice for its 2026 Annual Meeting on May 7, 2026, at 8:00 a.m. Central Time, held virtually. Shareholders can vote on the election of eight director nominees, advisory approval of named executive officers' compensation, and ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026. Proxy materials are available online at www.proxyvote.com, with requests for paper/email copies due by April 23, 2026, and voting deadlines of May 6, 2026 (general) or May 1, 2026 (Sun Life plan).

• ·Voting at www.proxyvote.com or virtually at www.virtualshareholdermeeting.com/GEHC2026.
• ·Request materials via www.proxyvote.com, 1-800-579-1639, or sendmaterial@proxyvote.com (include control number).
• ·Company address: 500 W. Monroe Street, Chicago, IL 60661.

19-03-2026

Neuraxis reported net sales growth of 32.9% YoY to $3.57M for the year ended December 31, 2025, from $2.69M in 2024, with gross profit rising 29.4% to $3.01M, reflecting strong gross margins around 84%. However, operating loss widened 9.4% to $7.83M due to sharp increases in selling expenses (+55.2%) and other costs, though net loss improved slightly by 5.3% to $7.80M. Cash and equivalents grew to $4.97M from $3.70M, supported by financing activities.

• ·Accounts receivable declined 20% to $195,703 as of Dec 31, 2025.
• ·Inventories increased to $257,132 from $44,328 YoY.
• ·Total assets grew to $6.40M from $4.76M.
• ·Net cash used in operations increased to $6.43M from $6.10M.

19-03-2026

Aebi Schmidt Group closed Q4 2025 with Order Intake up 46% YoY, a record Order Backlog over $1.2B, Net Sales up 6% YoY to $528M, and Adjusted EBITDA up 31% YoY to $48.1M (9.1% margin). However, North America Net Sales declined 2% YoY to $346M with legacy Shyft down 5%, and North America Adjusted EBITDA fell 4% YoY to $30M (margin down 20 bps), partially offset by Europe/RoW sales up 25% to $183M and Adjusted EBITDA up 234% to $18.1M. Full Year 2025 Net Sales grew 2% to $1.907B and Adjusted EBITDA rose 13% to $156M, with 2026 guidance of $1.95B-$2.15B sales and $175M-$195M Adjusted EBITDA.

• ·Merger with Shyft completed July 1, 2025; historical results on combined basis without pro-forma adjustments.
• ·Q4 2025 Net Income $8.8M (+$2.7M YoY from $6.1M).
• ·2026 guidance assumes walk-in-van recovery, no major geopolitical/inflation impacts; stronger H2 expected.
• ·Earnings call held March 19, 2026 at 8:30am ET.
• ·Leverage target <=2.0x by year-end 2026.